CTRI/2022/08/044762已完成未知
Evaluation of Dermatological Safety of Test Products by 24 Hours Patch Test under CompleteOcclusion on Adult Healthy Human Subjects
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age: 18-65 years (both inclusive) at the time of consent.
- •2. Sex: Males and non-pregnant/non-lactating females (preferably equal number of males and females).
- •3. Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).
- •4. Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application.
- •5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.
- •6. The subject is in good general health as determined by the Investigator on the basis of medical history.
- •7. Subjects are willing to maintain the test patches in designated positions for 24 Hours.
- •8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.
- •9. The subject must be able to understand and provide written informed consent to participate in the study.
- •10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instructions given.
排除标准
- •1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.
- •2. Medication which may affect skin response and/or past medical history.
- •3. Subject having history of diabetes
- •4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
- •5. Subject suffering from any active clinically significant skin diseases which may contraindicate.
- •6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.
- •7. Participation in any patch test for irritation or sensitization within the last four weeks.
- •8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).
- •9. Use of any:
- •i.Ã? Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.
- •ii.Ã? Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application.
- •iii.Ã? Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and/or eye drops are permitted)
- •10. Topical drugs used at application site.
- •11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous.
- •12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigatorââ?¬•s judgment, makes the subject ineligible or places the subject at undue risk.
- •13. Subject with known allergy or sensitization to medical adhesives, bandages.
- •14. Participation in other patch study simultaneously.
研究者
相似试验
已完成
不适用
Primary Irritation Patch Test (24-hour occlusion) on Adult Healthy Human Subjects with Sensitive Skin.CTRI/2023/02/049744Honasa Consumer Pvt. Ltd.26
已完成
不适用
Primary Irritation Patch Test (24-hour Occlusion for Sensitive Skin)CTRI/2023/05/052748Honasa Consumer Pvt. Ltd.26
已完成
不适用
Primary Irritation Patch Testing (PIPT)CTRI/2022/06/043319ITC Life Sciences Technology Centre25
已完成
不适用
Primary Irritation Patch Test for Sensitive Skin (Single Application 24-hour Occlusion).CTRI/2024/03/064349Honasa Consumer Ltd.25
已完成
Unknown
Primary Irritation Patch Test on Normal skin under complete occlusion.CTRI/2023/11/059923Transformative Learning Solutions Pvt Ltd.24